Guillermo Marmol

EDS provides a broad portfolio of business and technology solutions to help its clients worldwide improve their business performance. EDS’ core portfolio comprises information-technology, applications and business process services, as well as information-technology transformation services. EDS’ A.T. Kearney subsidiary is one of the world’s leading high-value management consultancies

Perot Systems Corp. is a worldwide provider of information technology services and e-business solutions to a broad range of clients. It emphasizes developing and integrating information systems, operating and improving technology and business processes, and helping clients transform their businesses. The company helps companies take full advantage of e-business by leveraging their traditional strengths and technologies into digital marketplaces. It is Headquartered in Plano, Texas.

Vitamin Shoppe, Inc. engages in the marketing of nutritional products. It offers vitamins, minerals, specialty supplements, herbs, sports nutrition, homeopathic remedies, green living products, and natural beauty aids. The company was founded in 1977 and is headquartered in Secaucus, NJ.

Luminant Worldwide Corp. provides Internet and electronic commerce professional services. It services include, strategy consulting, creative solutions, technology solutions and ongoing services. The company was founded in August 1998 and is headquartered in Houston, TX.

McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY.

Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada.